Abstract
Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative disease (PTLD) continues to be a rare but severe complication following transplantation. EBV viral load is used as a tool to identify patients at risk for developing PTLD. However, studies on EBV viral load are hard to compare since study design as well as EBV detection method and calculation of results are highly variable. In the majority of cases EBV viral load is increased in patients with PTLD compared to patients without disease. There is, however, some overlap. Some individual patients with only low viral load show PTLD while others show the opposite. The major future goals will be to standardize EBV-DNA detection in order to generate comparable data in different centers and to establish cut-off values to distinguish patients with PTLD from patients without with a high precision.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Walker RC, Marshall WR Strickler JG, Wiesner RH, Velosa lA, Habermann TM, McGregor CG, Paya CV (1995) Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 20:1346–1353
Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S, Ho M (1997) Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 176:1462–1467
Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, laffe ES, Sale GE, Horowitz MM, Witherspoon RP Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF, Jr., Deeg HJ (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94:2208–2216
Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95:1502–1505
Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551–555
Paya CV, Fung JJ, Naselnik MA. Kieff E, Green M. Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS (1999) Epstein-Barr virus related posttransplant lymphoproliferative disorders. Transplantation 68:1517–1525
Rooney CM, Smith CA, Ng CY, Loftin S, Li C, R.A. K, Brenner MK, Heslop H (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9–13
Rooney CM, Smith CA, Ng CY Loftin SK, Sixbey IW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555
Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L (1999) Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol 37:1113–1116
Beck R, Westdorp I, Jahn G, Schafer H, Kanz L, Einsele H (1999) Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation. J Clin Microbiol 37:3430–3431
Niesters HGM, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus ADME (2000) Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 38:712–715
Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM (2000) Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 111
Stevens SJ, Verschuuren EAM, Pronk I, van der Bij W, Harmsen MC, The H, Meijer CJLM, van der Brule AJC, Middeldorp JM (2001) Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97:1165–1171
Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G, Lake A, Proctor S, Taylor P, Clements GB, Jarret RF (1999) Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin’s disease. Int J Cancer 84:442–448
Bai X, Hosler G, Rogers BB, Dawson DB, Scheuermann R (1997) Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorders. Clin Chem 43:1843–1849
Green M, Bueno J, Rowe D, Mazariegos G, Qu L, Abu-Almagd K, Reyes J (2000) Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70:593–596
Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814
Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, Maccario R, Fiocchi R, Gerna G (2000) High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 38:613–619
Vajro P, Lucariello S, Migliaro F, Sokal E, Gridelli B, Vegnente A, lorio R, Smets F, Quinto I, Scala G (2000) Predictive value of Epstein-Barr virus genome copy number and BZLFl expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. J Infect Dis 181:2050–2054
Lucas KG, Filo R Heilman DK, Lee CH, Emanuel DJ (1998) Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Blood 92:3977–3978
Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, Lee CH, Emanuel DJ (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91:3654–3661
Riddler SA, Breinig MC, McKnight JL (1994) Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84:972–984
Mutimer D, Kaur N, Tang H, Singhal S, Shaw J, Whitehead L, Rickinson AGN (2000) Quantification of Epstein-Barr virus DNA in the blood of adult liver transplant recipients. Transplantation 69:954–959
Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA (1995) Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60:547–554
Rowe DT, Qu L, Reyes N, Jabbour NJ, Yunis E, Putnam P, Todo S, Green M (1997) Use of quantitative competitive PGR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35:1612–1615
Hoshino Y, Kimura H, Kuzushima K, Tsurumi T, Nemoto K, Kikuta A, Nishiyama Y, Kojima S, Matsuyama T, Morishima T (2000) Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load. Bone Marrow Transplant 26:199–201
Gartner BC, Schäfer H, Marggraf K, Eisele G, Schäfer M, Sester M, Sester U, Einsele H, Müller-Lantzsch N (2001) Epstein-Barr virus load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease after. Manuscript submitted 2001
Sester M, Sester U, Gärtner B, Heine G, Girndt M, MueUer-Lantzsch N, Meyerhans A, Köhler H (2001) Levels of virus-specific CD4 T-cells correlate with cytomegalovirus control and predict virus-induced disease following renal transplantation. Transplantation 71:1287–1294
Katz BZ, Saini U (1992) Presence of the diffuse early antigen of Epstein-Barr virus in lymphomas and lymphoproliferative disorders. Am J Pathol 140: 1247–1254
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gärtner, B.C., Fischinger, J., Schäfer, H., Einsele, H., Roemer, K., Müller-Lantzsch, N. (2002). Epstein-Barr Viral Load as a Tool to Diagnose and Monitor Post-Transplant Lymphoproliferative Disease. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive